Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients — CARES10

Primary Immunodeficiency Disease Clinical Trial

Official title:
A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients

Status Completed

Clinical Trial Summary

The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03961009
Study type	Interventional
Source	Kedrion S.p.A.
Contact
Status	Completed
Phase	Phase 3
Start date	April 30, 2019
Completion date	December 21, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03677557` - Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment	Phase 4
Completed	`NCT02810444` - Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID	Phase 3
Enrolling by invitation	`NCT01150240` - Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland	N/A
Recruiting	`NCT04944979` - Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)	Phase 3
Completed	`NCT02627300` - Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial	Phase 3
Not yet recruiting	`NCT03252548` - Pediatric Primary Immunodeficiency Disease (PID) in China	N/A
Completed	`NCT04842643` - An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease	Phase 3
Not yet recruiting	`NCT06089122` - Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG	Phase 3
Not yet recruiting	`NCT06150833` - Efficacy and Safety and Pharmacokinetics of Boya IVIG	Phase 3